Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jpm.2008.9864 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opioid-induced Esophageal Dysfunction Masquerading as Type I Achalasia.
J Neurogastroenterol Motil
October 2024
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
COVID-19 infection masquerading as recurrent apnoea in acute opioid overdose.
Arh Hig Rada Toksikol
July 2022
Qazvin University of Medical Sciences, Qazvin, Iran.
Anodyne by Design; Measuring the Prevalence of Esoteric Designer Opioids in Pain Management Patients.
J Anal Toxicol
July 2018
Department of Research & Development, MedTox Laboratories, Laboratory Corporation of America Holdings, St. Paul, MN, USA.
Article Synopsis
- The rise of illicit opioids, often disguised as prescription medications, poses serious public health risks due to unknown potencies and higher overdose potential, especially with drugs like fentanyl.
- Methods were developed to accurately identify and measure fentanyl and 18 designer opioids in urine samples, specifically targeting those from pain management patients.
- In a study of pain management patients, 25% of those with heroin in their system tested positive for designer opioids, while less than 1% tested positive in random pain samples, highlighting a significant correlation between heroin use and designer opioid exposure.
Methadone-Associated Hypoglycemia in Chronic Renal Failure Masquerading as an Insulinoma.
Pain Med
September 2018
Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA.
Opana-induced thrombotic microangiopathy masquerading as thrombotic thrombocytopenic purpura.
Oxf Med Case Reports
June 2017
Department of Pulmonary and Critical Care Medicine, University of Tennessee Chattanooga, Chattanooga, TN 37403, USA.
Opana (oxymorphone) is a powerful semi-synthetic opioid agonist used for chronic pain management that is ingested orally. However, improper injection of Opana can lead to a rare and fatal blood disorder known as thrombotic microangiopathy. Opana-induced thrombotic microangiopathy can be easily mistaken for thrombotic thrombocytopenic purpura (TTP), leading to the initiation of therapeutic plasma exchange.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!